MAPK3 and ovarian serous adenocarcinoma: The potential clinical relevance of these findings led us to explore the hypothesis of targeting ERK5 and ERK1/2 routes in an ex vivo 3D model (HuP3D) that uses ovarian serous cancer cells obtained from patient biopsies, and which are cultured in a 3D matrix made with plasma from the same patient (Figure 6A).